Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Lymphoid Hematological Malignancies Clinical Trial

Official title:
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Status Not yet recruiting

Clinical Trial Summary

Clinical Trial Description

This is a single-arm, single-center, open clinical study to evaluate the safety and efficacy of GC022F injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04626908
Study type	Interventional
Source	Zhejiang University
Contact	He Huang, MD
Phone	86-13605714822
Email	hehuangyu@126.com
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	November 20, 2020
Completion date	June 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02282358` - Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma	Phase 1/Phase 2
Recruiting	`NCT04283006` - A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies	Early Phase 1
Completed	`NCT03376958` - Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma	Phase 4